Advanced Search
Figures

Fig. 1

Number of published papers per/year on Transcranial Magnetic Stimulation. Medline search updated to December 2008. Key words used are “Transcranial magnetic stimulation” (left bars) and “repetitive TMS” (right bars).

Fig. 2

Left panel (Conventional rTMS). From the top: examples of 10 s of rTMS at 1 Hz (first trace) and at 5 Hz (second trace); 1 s of rTMS at 10 Hz and a typical example of 20 Hz application for therapeutic purposes (trains of 2 s interleaved by a pause of 28 s). Right panel (Patterned rTMS). From the top: 20 s of continuous theta burst (first trace); intermittent theta burst (second trace) and intermediate theta burst (third trace). The fourth trace represents protocols of quadripulse stimulations (QPS).

Abstract

This article is based on a consensus conference, which took place in Certosa di Pontignano, Siena (Italy) on March 7–9, 2008, intended to update the previous safety guidelines for the application of transcranial magnetic stimulation (TMS) in research and clinical settings.

Over the past decade the scientific and medical community has had the opportunity to evaluate the safety record of research studies and clinical applications of TMS and repetitive TMS (rTMS). In these years the number of applications of conventional TMS has grown impressively, new paradigms of stimulation have been developed (e.g., patterned repetitive TMS) and technical advances have led to new device designs and to the real-time integration of TMS with electroencephalography (EEG), positron emission tomography (PET) and functional magnetic resonance imaging (fMRI). Thousands of healthy subjects and patients with various neurological and psychiatric diseases have undergone TMS allowing a better assessment of relative risks. The occurrence of seizures (i.e., the most serious TMS-related acute adverse effect) has been extremely rare, with most of the few new cases receiving rTMS exceeding previous guidelines, often in patients under treatment with drugs which potentially lower the seizure threshold.

The present updated guidelines review issues of risk and safety of conventional TMS protocols, address the undesired effects and risks of emerging TMS interventions, the applications of TMS in patients with implanted electrodes in the central nervous system, and safety aspects of TMS in neuroimaging environments. We cover recommended limits of stimulation parameters and other important precautions, monitoring of subjects, expertise of the rTMS team, and ethical issues. While all the recommendations here are expert based, they utilize published data to the extent possible.

A Consensus Statement from the International Workshop on “Present and Future of TMS: Safety and Ethical Guidelines”, Siena, March 7–9, 2008.

1Giuliano Avanzini, Neurocienze Cliniche, Istituto Nazionale Neurologico “C. Besta, Milano, Italy.Sven Bestmann, Sobell Department of Motor Neuroscience and Movement Disorders, UCL Institute of Neurology, London, UK.Alfredo Berardelli, Department of Neurological Sciences and Neuromed Institute, University of Rome “La Sapienza”, Roma, Italy.Carmen Brewer, National Institute on Deafness and other Communication Disorders, National Institutes of Health, Bethesda, MD, USA.Turhan Canli, Department of Psychology, Stony Brook University, New York, USA.Roberto Cantello, Dipartimento di Medicina Clinica e Sperimentale, Sezione Neurologia, Università del Piemonte Orientale “A. Avogadro”, Novara, Italy.Robert Chen, Toronto Western Research Institute and Division of Neurology, Department of Medicine, University of Toronto, Canada.Joseph Classen, Department of Neurology, University of Leipzig, Germany.Mark Demitrack, Neuronetics, Inc., Malvern, PA, USA.Vincenzo Di Lazzaro, Institute of Neurology, Univesità Cattolica, Roma, Italy.Charles M. Epstein, Department of Neurology, Emory University School of Medicine, Atlanta, USA.Mark S. George, Medical University of South Carolina, Charleston, SC, USA.Felipe Fregni, Berenson-Allen Center for Noninvasive Brain Stimulation, Beth Israel.Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.Risto Ilmoniemi, Department Biomed. Eng. and Computational Science (BECS), Helsinki, Finland.Reza Jalinous, Magstim Company, Boston, MA, USA.Barbara Karp, Combined NeuroScience IRB, National Institutes of Health, Bethesda, MD, USA.Jean-Pascal Lefaucheur, Service Physiologie, Explorations Fonctionnelles, Hôpital Henri Mondor, Créteil, France.Sarah Lisanby, Division of Brain Stimulation & Therapeutic Modulation, Columbia University College of Physicians and Surgeons, New York State Psychiatric Institute, New York, NY, USA.Sabine Meunier, Service de Réadaptation Fonctionnelle, Hôpital de la Salpêtrière, Paris, France.Carlo Miniussi, Cognitive Neuroscience Section, IRCCS San Giovanni di Dio Fatebenefratelli, Brescia, Italy.Pedro Miranda, Institute of Biophysics and Biomedical Engineering, Faculty of Science, University of Lisbon, Portugal.Frank Padberg, Klinik für Psychiatrie und Psychotherapie, Ludwig-Maximilians-Universität München, Germany.Walter Paulus, Department of Clinical Neurophysiology, University of Goettingen, Germany.Angel Peterchev, Division of Brain Stimulation and Therapeutic Modulation, Department of Psychiatry and Department of Electrical Engineering, Columbia University, New York, NY, USA.Corinna Porteri, Bioethics Unit, IRCCS San Giovanni di Dio Fatebenefratelli, Brescia, Italy.Miriam Provost, Medical Devices Biologics Consulting Group, Inc., Athens, GA, USA.Angelo Quartarone, Dipartimento di Neuroscienze, Scienze Psichiatriche ed Anestesiologiche, Università di Messina, Italy.Alexander Rotenberg, Department of Neurology, Division of Epilepsy and Clinical Neurophysiology, Children’s Hospital, Harvard Medical School, Boston, MA, USA.John Rothwell, Sobell Department, Institute of Neurology, Queen Square, London, UK.Jarmo Ruohonen, Nexstim Ltd., Helsinki, Finland.Hartwig Siebner, Danish Research Centre for Magnetic Resonance, Copenhagen University Hospital Hvidovre, Denmark.Gregor Thut, Centre for Cognitive Neuroimaging, Department of Psychology, University of Glasgow, UK.Josep Valls-Solè, Neurology Department, Hospital Clínic, University of Barcelona, SpainVincent Walsh, Institute of Cognitive Neuroscience and Department of Psychology University College London, London, UK.Yoshikatzu Ugawa, Department of Neurology, School of Medicine, Fukushima Medical University, Japan.Abraham Zangen, Department of Neurobiology, The Weizmann Institute of Science, Rehovot, Israel.Ulf Ziemann, Klinikum der Johann Wolfgang Goethe-Universität Frankfurt am Main, Germany.

 

Linked Articles

  • Simone Rossi, Mark Hallett, Paolo M. Rossini, Alvaro Pascual-Leone
    DOI: http://dx.doi.org/10.1016/j.clinph.2010.12.037
    Clinical Neurophysiology, Vol. 122, Issue 8
  • Related Articles

    Searching for related articles..

    Advertisement